The FDA has approved a new indication for Kogenate FS (antihemophilic factor VIII recombinant), from Bayer HealthCare, for routine prophylaxis...
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease. This product is indicated for adults, adolescents and children of all ages.
Bayer has received approval from the European Commission of Kovaltry for the treatment of hemophilia A in patients of all...
Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) announced at ASCO...
Diffuse bleeding after chest wall and spine resection represents a major problem in General Thoracic Surgery. Several fibrin sealants (FS)...
The FDA has approved Bayer’s Kovaltry (recombinant Factor VIII), for the treatment of hemophilia A in children and adults. The...
Roche, the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) announced updated data from the phase III APHINITY study in HER2-positive early breast cancer.
BioCardia, Inc. announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP Cell Therapy Heart Failure Trial (clinicaltrials.gov Identifier: NCT02438306), for which FDA granted Breakthrough Designation
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...